Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16922004 | 0.89 | HRH3 (0.33) | HRH3ALDH1A1 | |
| SCHEMBL17853433 | 0.86 | NPC1 (0.40) | HRH3ALDH1A1NPC1TP53TSHR | |
| SCHEMBL16921993 | 0.82 | HRH3 (0.38) | HRH3NOS1NOS2 | |
| SCHEMBL16921861 | 0.81 | NPC1 (0.35) | ALDH1A1NPC1TP53TSHRRAB9A | |
| SCHEMBL16921799 | 0.81 | ALDH1A1 (0.34) | ALDH1A1NPC1TP53RAB9ASMN1; SMN2 | |
| SCHEMBL16922049 | 0.81 | ALDH1A1 (0.34) | HRH3ALDH1A1NOS1NOS2 | |
| SCHEMBL15597833 | 0.80 | ALDH1A1 (0.34) | HRH3ALDH1A1 | |
| SCHEMBL16922031 | 0.77 | CTH (0.36) | NOS1NOS2 | |
| SCHEMBL16921832 | 0.77 | CTH (0.36) | ALDH1A1NPC1TP53TSHRRAB9A | |
| SCHEMBL16921780 | 0.77 | ALDH1A1 (0.33) | ALDH1A1NPC1TP53TSHRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170327478-A1 | CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS | SOVA PHARMACEUTICALS, INC. | 2017-11-16 | — | — | US | disclosed |
| US-9725426-B2 | Cystathionine-γ-lyase (CSE) inhibitors | SOVA PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20150272934-A1 | USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS | SOVA PHARMACEUTICALS, INC. | 2015-10-01 | — | — | US | disclosed |
| US-20150266837-A1 | CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS | SOVA PHARMACEUTICALS, INC. | 2015-09-24 | — | — | US | disclosed |
| US-20150202186-A1 | CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN | SOVA PHARMACEUTICALS, INC. | 2015-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327478-A1 | CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS | CBS, CTH, BHMT | HRH3 3120/4885ALDH1A1 954/4885NOS1 907/4885 |
| US-20150266837-A1 | CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS | CBS, CTH, BHMT | HRH3 3120/4885ALDH1A1 954/4885NOS1 907/4885 |
| US-20150202186-A1 | CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN | CBS, CTH, MTR | HRH3 1850/4885ALDH1A1 1037/4885NOS1 2246/4885 |
| US-20150272934-A1 | USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS | HIF1AN, CBS, COXFA4L2 | HRH3 67/4885ALDH1A1 974/4885NOS1 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.